JP2024542823A5 - - Google Patents

Info

Publication number
JP2024542823A5
JP2024542823A5 JP2024533832A JP2024533832A JP2024542823A5 JP 2024542823 A5 JP2024542823 A5 JP 2024542823A5 JP 2024533832 A JP2024533832 A JP 2024533832A JP 2024533832 A JP2024533832 A JP 2024533832A JP 2024542823 A5 JP2024542823 A5 JP 2024542823A5
Authority
JP
Japan
Prior art keywords
seq
antibody
antigen
binding fragment
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024533832A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024542823A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/081031 external-priority patent/WO2023107957A1/en
Publication of JP2024542823A publication Critical patent/JP2024542823A/ja
Publication of JP2024542823A5 publication Critical patent/JP2024542823A5/ja
Pending legal-status Critical Current

Links

JP2024533832A 2021-12-06 2022-12-06 アンタゴニスト抗npr1抗体およびその使用方法 Pending JP2024542823A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163286476P 2021-12-06 2021-12-06
US63/286,476 2021-12-06
US202263310078P 2022-02-14 2022-02-14
US63/310,078 2022-02-14
PCT/US2022/081031 WO2023107957A1 (en) 2021-12-06 2022-12-06 Antagonist anti-npr1 antibodies and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2024542823A JP2024542823A (ja) 2024-11-15
JP2024542823A5 true JP2024542823A5 (enExample) 2026-01-28

Family

ID=85017755

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024533832A Pending JP2024542823A (ja) 2021-12-06 2022-12-06 アンタゴニスト抗npr1抗体およびその使用方法

Country Status (11)

Country Link
US (1) US12606618B2 (enExample)
EP (1) EP4444416A1 (enExample)
JP (1) JP2024542823A (enExample)
KR (1) KR20240112973A (enExample)
AU (1) AU2022408149A1 (enExample)
CA (1) CA3239802A1 (enExample)
CL (2) CL2024001632A1 (enExample)
CO (1) CO2024008879A2 (enExample)
IL (1) IL313265A (enExample)
MX (1) MX2024006812A (enExample)
WO (1) WO2023107957A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210082207A (ko) 2018-10-23 2021-07-02 리제너론 파아마슈티컬스, 인크. 항-npr1 항체 및 이의 용도
US12325752B2 (en) 2020-12-18 2025-06-10 Regeneron Pharmaceuticals, Inc. Immunoglobulin proteins that bind to NPR1 agonists

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
PT2281843T (pt) * 2000-06-16 2017-01-02 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2004011618A2 (en) 2002-07-29 2004-02-05 Hmgene, Inc. Methods of identifying adipocyte specific genes, the genes identified, and their uses
US20080214437A1 (en) 2002-09-06 2008-09-04 Mohapatra Shyam S Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトil−6受容体に対する高親和性抗体
GB0624500D0 (en) 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
US20100310561A1 (en) 2007-06-06 2010-12-09 Boehringer Ingelheim International Gmbh Natriuretic fusion proteins
WO2010065293A1 (en) 2008-12-03 2010-06-10 Boehringer Ingelheim Pharmaceuticals Inc. Antibodies for guanylyl cyclase receptors
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
AU2010273585B2 (en) 2009-07-13 2015-04-23 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
SMT202600080T1 (it) 2010-02-08 2026-03-09 Regeneron Pharma Topo con catena leggera comune
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
US9451770B2 (en) 2012-06-08 2016-09-27 Charles Despres Method of activating immune response in plants
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
US9987330B2 (en) * 2013-12-05 2018-06-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of treating or preventing pruritis by blocking natriuretic polypeptide B
CA2874083C (en) 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
WO2016131943A1 (en) 2015-02-20 2016-08-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of obesity and complications arising therefrom including type 2 diabetes
WO2017209553A2 (ko) 2016-06-03 2017-12-07 사회복지법인 삼성생명공익재단 환자 유래 세포를 이용한 항체 스크리닝 방법
US20190248888A1 (en) 2016-10-20 2019-08-15 Regeneron Pharmaceuticals, Inc. Methods of lowering blood glucose levels
US20190135804A1 (en) 2017-11-03 2019-05-09 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Compositions and methods for the inhibition of pruritus
CN112020518A (zh) * 2018-02-01 2020-12-01 辉瑞公司 靶向cd70的嵌合抗原受体
KR20210082207A (ko) 2018-10-23 2021-07-02 리제너론 파아마슈티컬스, 인크. 항-npr1 항체 및 이의 용도
EP3898700A1 (en) 2018-12-18 2021-10-27 Novartis AG Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
DK3941946T3 (da) * 2019-03-20 2025-03-24 Univ California Claudin-6-antistoffer og lægemiddelkonjugater
US11066469B2 (en) 2019-06-12 2021-07-20 Novartis Ag Natriuretic peptide receptor 1 antibodies and methods of use
EP4259661A1 (en) 2020-12-14 2023-10-18 Novartis AG Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof
US12325752B2 (en) 2020-12-18 2025-06-10 Regeneron Pharmaceuticals, Inc. Immunoglobulin proteins that bind to NPR1 agonists
WO2022155324A1 (en) * 2021-01-15 2022-07-21 The Rockefeller University Neutralizing anti-sars-cov-2 antibodies
CN118159290A (zh) 2021-10-11 2024-06-07 瑞泽恩制药公司 通过施用抗npr1抗体来影响血液动力学变化的方法

Similar Documents

Publication Publication Date Title
JP2022505604A5 (enExample)
JP7559112B2 (ja) グルカゴン様ペプチド1受容体アゴニストおよびそれらの使用
KR101160385B1 (ko) 페길화된 Aβ FAB
JP2024542823A5 (enExample)
US20120039882A1 (en) Vascular Disease Therapies
JP2011504872A5 (enExample)
WO2011103700A1 (zh) 一种全人源抗her2单克隆抗体、其制备方法及用途
RU2014106652A (ru) Ингибирующие моноклональные антитела против фактора xii/xiia и их применения
JP2024503784A5 (enExample)
US12606618B2 (en) Antagonist anti-NPR1 antibodies and methods of use thereof
JP2024537284A5 (enExample)
JP2024177399A (ja) 呼吸器疾患の治療のための汎elr+cxcケモカイン抗体
IL294941A (en) Inhibitors and their uses
JP2024505195A5 (enExample)
JP2024526930A (ja) 線維性疾患を緩和または治療するための薬物組成物またはキットおよびその応用
IL301713A (en) Methods for treating dermatomyositis
NZ773064B2 (en) Anti-npr1 antibodies and uses thereof
NZ773064A (en) Anti-npr1 antibodies and uses thereof
WO2022228380A1 (en) Anti-cxcr2 antibodies and uses thereof
CN120230210A (zh) 一组sh1同源簇全人源tsh受体阻断性单克隆抗体及其制备方法和应用
CN120230208A (zh) 一组sh23同源簇全人源tsh受体阻断性单克隆抗体及其制备方法和应用
CN118414354A (zh) 拮抗剂抗npr1抗体及其使用方法
EA052748B1 (ru) Антагонистические анти-npr1 антитела и способы их применения
WO2026072993A1 (en) Methods for treatment of metabolic dysfunction-associated steatohepatitis with an anti-tl1a antibody
RU2019127917A (ru) Антитела-миметики fgf21 и пути их применения